What Is the CJC 1295 / Ipamorelin Research Cycle?
The research cycle typically lasts between six and eight weeks. During this time participants inject CJC-1295, a long-acting growth hormone releasing hormone (GHRH) analog, once or twice daily, and Ipamorelin, a selective GHRP, once or twice daily as well. The two peptides are designed to act synergistically: CJC-1295 stimulates the pituitary gland to release growth hormone over an extended period, while Ipamorelin triggers the secretion of growth hormone by mimicking ghrelin’s action on its receptor. Together they produce a sustained rise in circulating growth hormone and insulin-like growth factor 1 (IGF-1), which are key drivers of muscle protein synthesis and fat metabolism.
The cycle is often used as part of a larger peptide stack that may include other agents such as MK-677, GHRP-6 or human chorionic gonadotropin (HCG). The stacking strategy allows users to fine-tune their hormonal environment, maximizing anabolic effects while minimizing side effects. For example, pairing CJC-1295/Ipamorelin with a modest dose of testosterone replacement can enhance muscle hypertrophy and accelerate recovery from intense training sessions.
Your cart is currently empty
If you are looking to purchase CJC-1295 or Ipamorelin for research purposes, most suppliers require a valid prescription or a research license. It is common for customers to create an account on the vendor’s website, add the peptides to their cart and proceed through a verification process that confirms they meet the legal requirements for procurement. Once the cart contains the desired products, users can review dosage instructions, shipping details and payment options before completing the transaction.
What is the cycle CJC 1295 / Ipamorelin, and how does it impact peptide stacking?
The core benefit of this research cycle lies in its ability to elevate growth hormone levels without directly stimulating testosterone receptors or other steroid pathways. Because CJC-1295 has a long half-life (approximately 8–12 hours) and can be dosed once daily, it provides steady stimulation of the pituitary gland. Ipamorelin’s short action period (30–60 minutes) allows for flexible timing around workouts, often administered pre-workout or post-workout to maximize anabolic signaling.
When stacked with other peptides, the CJC-1295/Ipamorelin pair can amplify the effects of each individual compound. For instance, a stack that includes growth hormone secretagogues such as GHRP-6 may benefit from the sustained GH release of CJC-1295, while Ipamorelin’s selective receptor activation reduces the risk of side effects like increased appetite or water retention. Similarly, adding peptides that influence insulin sensitivity (e.g., MK-677) can complement the IGF-1 surge induced by the stack, promoting better nutrient partitioning and muscle growth.
In practice, users typically follow a schedule where they inject CJC-1295 in the morning and Ipamorelin either in the morning or before bed. This dual timing ensures that growth hormone levels peak at different times of day, providing a more consistent anabolic environment. After completing the cycle, many practitioners recommend a post-cycle therapy phase that may include natural HGH boosters (such as L-arginine or DHEA) and nutritional support to help the endocrine system recover fully.
Overall, the CJC-1295/Ipamorelin research cycle is valued for its potent ability to increase growth hormone production in a controlled manner. When integrated thoughtfully into a peptide stack, it offers a powerful tool for enhancing muscle hypertrophy, fat loss, recovery speed and overall metabolic health without the hormonal imbalances associated with many anabolic steroids.
